Atria Medical Inc
Biobeat Medical Ltd.
Bioscan Technologies
DECOM Clinical Decision Support Ltd.
TopSpin Medical Inc.
Rcadia Medical Imaging Ltd.
Actelion Pharmaceuticals Israel
Vascular Biogenics Ltd.
MGVS
GeneGrafts Ltd.
TheraVitae Ltd.
NesStent Ltd.
B-Balloon Ltd.
Existent Ltd.
Derio Medical Instruments Ltd.
Sector: Medical Devices
Sub-Sector: Disposable; Implantable; Therapeutic Devices
Medical Field: Cardiovascular
Est.: 2004
Stage: Seed
Atria is a start-up company developing an
implantable device to enhance and improve the
clinical symptoms of Congestive Heart Failure
patients by reducing pulmonary edema. The
company's product is an implantable "valve" to
control the intra-arterial pressure. The device
is implanted by aminimally invasive procedure in
the wall separating the two atria.
Contact Info:
Ori Ben Amotz
POB 3132 Caessaria 38900, Israel
972-4-632-7640/1
Sector: Medical Devices
Sub-Sector: Diagnostic
Medical Field: Cardiovascular
Est.: 2004
Stage: Revenue
http://biobeatmedical.com
Biobeat Medical develops and markets special
ultrasound Doppler devices for transcranial (TCD)
and peripheral vascular applications. The
company's core technology is digital ultrasound
Doppler, and its' products are designed for
measurements of blood flow velocities in the
vessels of the brain and the peripheral
circulation. The company's products include the
SONARA, a fully integrated stand-alone system,
and the SONARA/tek, a plug-in module that can
connect to any PC via a USB connection. The
products are regulatory approved, and Biobeat
Medical conforms to the highest QA standards.
Contact Info:
Dr. Dan Manor, CEO
info@biobeatmedical.com
P.O. Box 264, Kadima, Israel
972-9-744-1692
972-9-745-0621
Sector: Medical Devices
Sub-Sector: Diagnostic
Medical Field: Cardiovascular
Est.: 2000
Stage: Clinical
http://www.bioscantech.com
Bioscan is a start-up company focusing on the
development of optical ultrasonic technology for
the use in diagnosis and treatment of
cardiovascular diseases. The company's platform
technology, SonarLight, combines the use of a
laser and ultrasound technology operating within
a fiber optic. By utilizing laser to generate
ultrasound, Bioscan is expected to be able to
reduce the size of its ultrasound probe to that
of an optic fiber thereby transforming the
diagnosis and treatment of intravascular
diseases. The low production costs of fiber optic
technology will allow for competitive pricing of
disposables compared to existing technologies.
Contact Info:
Avram Matcovitch, CEO
Ha'Carmel 5, Industrial Zone, Yokneam, 20692 Israel
972-4-993-7363
Sector: Medical Devices
Sub-Sector: Imaging
Medical Field: Cardiovascular
Est.: 2004
Stage: Seed
http://www.decomcds.com
DECOM Clinical Decision Support Ltd. - a medical
software company develops and offers the dCARDIO
product suite - a patient-centric diagnostic
image and information management solution to both
OEMs and end users - cardiology group practices,
small hospitals, imaging centers, and solo
practitioners.
Incorporating data from diverse institutions,
dCARDIO makes all patient's diagnostic images
accessible at the point of care - Anytime and
Anywhere. With dCARDIO, review workstation
functionality traditionally existing only in
diagnostic labs, becomes available in every
physician's office. The ability to maintain a
personal image collection on physician's laptop
makes the product core functionality portable.
Due to its versatile architecture, the core
product can be integrated with electronic medical
record systems in a single application. As a
result, physicians review, compare and analyze
patient's diagnostic images along with the
electronic medical record, facilitating the
efficient detection of changes in the clinical
situation.
The company's mission is to become a market
leader in delivering diagnostic decision support
tools for cardiology practitioners.
Contact Info:
Vladimir Boyko, President
info@decomcds.com
P.O.Box 421, Kiryat Ono, 55000
972-54-459-0589
972-3-534-8918
Sector: Medical Devices
Sub-Sector: Imaging
Medical Field: Cardiovascular
Est.: 1999
Stage: Clinical
http://www.topspin.co.il
TopSpin Medical has developed an IntraVascular
MRI (IVMRI) catheter for local high-resolution MR
imaging of the coronary arteries, which
incorporates all magnetic field sources and
eliminates the need for external magnets and a
bulky and expensive MRI scanner. TopSpin's IVMRI
catheter will potentially enable interventional
cardiologists to guide therapy to vulnerable
plaques.
Contact Info:
Eyal Kolka, COO
info@topspin.co.il
2 Yodfat St. Global Park, Lod Northern Industrial Area 71291, Israel
972-8-920-0033
972-8-928-1233
imaging of the coronary arteries.
Sector: Medical IT
Sub-Sector: Software and Hardware
Medical Field: Cardiovascular
Est.: 2003
Stage: Seed
http://www.rcadia.com
Rcadia is engaged in the development of
SmartHeart - a software for automated CT
Angiography (CTA) diagnostics for the detection,
assessment and reporting of Coronary Artery
Disease.
Rcadia specializes in CAD (Computer Aided
Diagnostics) for blood vessel analysis
applications. While the main focus is on coronary
CTA, we aim to offer a wider range of solutions
for additional clinical applications.
For the first time, CT scanners can image lesions
of the native coronary arteries with
unprecedented clarity and resolution - a vital
and unique breakthrough in the radiology and
cardiology fields. Rcadia's SmartHeart CAD will
play a pivotal role in this revolution.
SmartHeart, Rcadia's CTA flagship product will
assist cardiologists and radiologists in medical
image analysis to:
Detect calcified plaque, soft plaque, stenosis & aneurysm
Measure the volume of plaque formations
Segment and locate blood vessels in CT studies
Measure the degree of stenosis/aneurysm
Map pathology locations in anatomical structures (segments)
Contact Info:
Shai Levanon, CEO
2 Hayozma, Tirat Carmel 39032, Israel
+972-4-8583010
+972-4-8582070
Sector: Pharmaceuticals
Sub-Sector: New Chemical Entity
Medical Field: Cardiovascular
Est.: 2004
Stage: Revenue
http://www.actelion.com
Actelion is an indepedent biopharmaceutical
company which brings to the market innovative
treatments for diseases of endothelium through
creative science. The company is rapidly growing
due to successful marketing of multiple
first-in-class small molecule compounds
discovered, developed and registered by the
company. On 2004 Actelion has opended an Israeli
subsidiary.
Contact Info:
Ran Frenkel, CEO
efrat.gur@actelion.com
3 Hayetzira St. Ramat-Gan 52521 Israel
972-3-612-5500
972-3-612-6600
Sector: Pharmaceuticals
Sub-Sector: New Chemical Entity
Medical Field: Cardiovascular
Est.: 2000
Stage: Pre-Clinical
http://www.vbl.co.il
Vascular Biogenics Ltd. (VBL) is a pharmaceutical
company dedicated to the development of
innovative therapies targeting the vascular wall.
Its extensive vascular expertise is utilized in
addressing the Cardiovascular and Cancer drug
markets.
Contact Info:
Dr. Emmanuel Elalouf, COO
contact@vbl.co.il
6 Jonathan Netanyahu, Or Yehuda, 60376 Israel
972-3-634-6450 (Ext. 103)
972-3-634-6449
Sector: Biotechnology
Sub-Sector: Tissue Engineering & Cell Therapy
Medical Field: Cardiovascular
Est.: 2000
Stage: Pre-Clinical
MGVS develops unique products for very large
patient populations who cannot be treated
adequately with current therapeutic modalities,
with a focus on cardiovascular related syndromes.
The Company's therapeutic products utilize the
patient's own (autologous) vascular cells,
modified by genes that are operative in natural
vascular processes. MGVS currently has two
products at different stages of development: 1)
angiogenesis therapy for patients with arterial
obstructive diseases of the legs and the heart;
2) bio-engineered grafts for use in bypass
surgery in the legs and in hemodialysis access
site. MGVS has recently closed a round of 4
million dollars, which will bring it to the
conclusion of Phase I studies.
Contact Info:
Dr. Moshe Flugelman, CEO
972-4-825-0832
972-4-825-0841
Sector: Biotechnology
Sub-Sector: Tissue Engineering & Cell Therapy
Medical Field: Cardiovascular
Est.: 2003
Stage: Seed
http://www.genegrafts.com
GeneGrafts is a new biotechnology company,
developing a novel therapy for atrial
fibrillation (AF). Atrial fibrillation is the
most common cardiac arrhythmia affecting 2.3
million Americans. Conventional therapy for AF is
based on medications taken daily, with
significant side effects. GeneGrafts is
developing a cell therapy approach using
autologous (extracted from the patient)
genetically modified cells that are delivered to
the patient's heart by catheterization. The
treatment is localized and involves a single
procedure.
Contact Info:
Dr. Yair Feld, CEO
972-4-854-6618
972-4-850-1246
Sector: Biotechnology
Sub-Sector: Tissue Engineering & Cell Therapy
Medical Field: Cardiovascular
Est.: 2003
Stage: Clinical
http://www.theravitae.com
TheraVitae is an emerging healthcare company
focused on using the patient's own cells in order
to treat a variety of disorders, especially
cardiovascular diseases. We are an international
company, based in Bangkok, Thailand and Kiryat
Weizmann, Israel, benefiting from collaborations
with eminent physicians and scientists,
affiliated with well-known medical and academic
institutions. We are committed to helping our
patients by developing and utilizing cutting-edge
science at its highest standards.
TheraVitae offers novel, state-of-the-art
therapies to people for whom existing medical
procedures cannot be used or were not successful.
We will offer hope to people who refuse to accept
that they have been condemned to physical
incapacitation, spending the rest of their lives
in suffering because they cannot enjoy the latest
medical technologies as the latter are not
available to them in their country.
The company is at clinical development stage and
focused on the development of cellular therapies
for cardiovascular and other disorders. The first
product developed by the Company is based on
autologous (patient's own cells) endothelial
progenitor cells and it is in clinical trial for
the treatment of angina pectoris.
Contact Info:
Valentin Fulga, MD, CEO
enquiries@theravitae.com
7, Pinchas Sapir St. Ness Ziona, 74410, Israel
972-8-940-9170
972-8-940-9167
Sector: Medical Devices
Sub-Sector: Disposable; Implantable; Therapeutic Devices
Medical Field: Cardiovascular
Est.: 2003
Stage: Seed
NesStent Ltd is a start up company developing
unique Stenting solutions and devices including:
1. A new stent concept for coronary bifurcations
2. A new catheter concept for precision delivery
of stents to bifurcations or other hard to stent
locations. 3. A novel stent to be inserted to the
Carotid bifurcation diverting emboli in the
Carotid artery, and by doing so preventi strokes.
Contact Info:
jonathan Eting
POBox 345, OR Yehuda 60200, Israel
972-3-634-4254
972-3-634-1565
Sector: Medical Devices
Sub-Sector: Disposable; Implantable; Therapeutic Devices
Medical Field: Cardiovascular
Est.: 2004
Stage: Pre-Clinical
http://www.bballoon.com
B-Balloon Ltd., an Israeli medical device
start-up, develops dedicated stents and stent
delivery systems that will safely allow the
placing of stents in Ostial and Bifurcation
lesions. These lesions are considered two of the
biggest unresolved challenges in Percutaneus
Coronary Intervention. Nevertheless, B-Balloon's
devices are not limited to the coronaries and may
be used in other vessels.
Contact Info:
Ziv Ehrenfeld, COO
ziv@bballoon.com
972-3-634-9990
972-3-634-9910
Sector: Medical Devices
Sub-Sector: Disposable; Implantable; Therapeutic Devices
Medical Field: Cardiovascular
Est.: 2003
Stage: Seed
Existent is developing a new cardiovascular stent.
Contact Info:
Dr. Motty Beyar, CEO
eilat@existent-med.com
Hasadnaot 3 st., Herzeliya 46728, Israel
972-9-970-4300
972-9-970-4318
Sector: Medical Devices
Sub-Sector: Disposable; Implantable;
Medical Field: Cardiovascular